End Stage Renal Disease clinical trials at UCSF
3 in progress, 2 open to eligible people
End stage renal disease is when the kidneys no longer work well enough to keep the body healthy. UCSF is recruiting for trials to help people with this condition. One trial is studying home blood pressure and dialysis treatment, and another is looking to improve kidney transplant outcomes and safety. Joining a clinical trial can help doctors find new treatments for end stage renal disease.
The Home Blood Pressure (BP) Trial
open to eligible people ages 18 years and up
The main study will be a two arm 10-month, cross-over randomized controlled trial of 200 participants treated with end-stage-kidney-disease treated with in-center hemodialysis in the Seattle and San Francisco area comparing a strategy of targeting home vs. pre-dialysis systolic blood pressure <140 mmHg to reduce rates of intradialytic hypotension. The target systolic blood pressure of <140 mmHg in both treatment groups will be achieved using an algorithm of dry weight adjustment and anti-hypertensive medication adjustment.
San Francisco, California and other locations
APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO)
open to all eligible people
The APOLLO study is being done in an attempt to improve outcomes after kidney transplantation and to improve the safety of living kidney donation based upon variation in the apolipoprotein L1 gene (APOL1). Genes control what is inherited from a family, such as eye color or blood type. Variation in APOL1 can cause kidney disease. African Americans, Afro-Caribbeans, Hispanic Blacks, and Africans are more likely to have the APOL1 gene variants that cause kidney disease. APOLLO will test DNA from kidney donors and recipients of kidney transplants for APOL1 to determine effects on kidney transplant-related outcomes.
San Francisco, California and other locations
A Study Testing the Use of a Perivascular Sirolimus Formulation (Sirogen) in ESRD Patients Undergoing AV Fistula Surgery
Sorry, not currently recruiting here
The primary study objective is to evaluate the benefit of the Sirolimus eluting Collagen implant (SeCI; Sirogen), a single dose prophylactic treatment delivered intraoperatively at the time of surgical creation of an arteriovenous fistula for hemodialysis vascular access.
San Francisco, California and other locations
Our lead scientists for End Stage Renal Disease research studies include Meyeon Park, MD Chi-yuan Hsu, MD.
Last updated: